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Jan J. Piek, MD, PHD, Martijn A. van Lavieren, MSCSEE PAGE 231S T-segment elevation myocardial infarction(STEMI) is considered a major contributor toglobal mortality and morbidity. The ﬁnal
necrotic infarct size has been identiﬁed as one of
the major predictors of the clinical outcome after
STEMI. In the recent decades, STEMI management
has evolved dramatically, now encompassing dedi-
cated STEMI networks, potent antithrombotic drugs,
and rapid achievement of myocardial reperfusion.
These therapeutic interventions in the acute phase
have resulted in a remarkable decline in cardiac
morbidity and mortality. Adjunctive therapies, next
to early coronary reperfusion, are considered the
major challenge to reduce infarct size and further
improve clinical outcome after STEMI and is topic
of intensive experimental and clinical research.
The use of beta-adrenergic receptor antagonists
(beta-blockers) is mandatory in the subacute phase
after acute myocardial infarction (AMI), resulting
in a decrease in mortality, life-threatening arrhyth-
mias, reinfarction, and recurrent ischemia (1). Current
practice guidelines recommend initiating oral admin-
istration of beta-blockers within the ﬁrst 24 h after
AMI as a ﬁrst-line treatment in secondary prevention
after AMI. However, it is recognized that the timing
of beta-blocker initiation may have a signiﬁcant
impact on the ﬁnal infarct size, suggesting that early
administration of beta-blockers during ongoing
ischemia might increase myocardial salvage. Intrave-
nous administration of a beta-blocker before reperfu-
sion has recently been shown to result in improved*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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disclose.cardiac recovery after STEMI by inhibition of sympa-
thetic activity during the acute phase of AMI (2).In this issue of JACC: Cardiovascular Interventions,
Er et al. (3) report a single-center, prospective, ran-
domized, controlled trial assessing the effect of
esmolol-induced tight heart rate and sympathetic
control in patients with STEMI. To control sympa-
thetic activity, they used a predeﬁned target heart
rate of 60 beats/min and a mean arterial blood pres-
sure of >65 mm Hg to guide continuous intravenous
beta-blocker administration that was started imme-
diately after primary percutaneous coronary inter-
vention (PCI). According to the study protocol, the
investigators randomized 101 patients, presenting
with Killip class I or II STEMI and in whom successful
PCI was performed within 6 h of STEMI onset. The
primary endpoint was the maximal change in
troponin T release from baseline to 48 h as a surrogate
marker for cardiac damage. The treatment strategy to
control sympathetic activity using continuous intra-
venous administration of esmolol limited troponin T
release by 34% compared with the placebo group, and
a similar reduction was observed in creatine kinase
and creatine kinase-myocardial band release. In
addition, esmolol almost halved the release of N-
terminal pro–B-type natriuretic peptide compared
with the control group.
The authors address the increasingly recognized
and timely topic of the efﬁcacy and safety of sympa-
thetic control by intravenous administration of beta-
blockers in the acute phase of myocardial infarction.
However, the present study used surrogate bio-
markers of myocardial damage as the primary and
secondary endpoints and did not perform magnetic
resonance imaging (MRI) to quantify ﬁnal infarct size,
which can be considered a limitation of the study
design. Unfortunately, the mechanisms responsible
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242for the favorable effects of early administration of
beta-blockers on surrogate biomarkers of myocardial
damage are not elucidated in the present study. In
addition, the sample size is relatively small, taking
into account the heterogeneity of the study popula-
tion, which involved both anterior and nonanterior
myocardial infarctions. As a result, the present study
should be considered a pilot study that warrants
further evaluation in a larger randomized, controlled
multicenter trial with a focus on elucidating the
mechanisms behind the effects of early administra-
tion of beta-blockers.
Recently, the METOCARD-CNIC (Effect of Meto-
prolol in Cardioprotection During an Acute Myocar-
dial Infarction) trial also reported the effect of early
intravenous metoprolol boluses in 270 anterior STEMI
patients undergoing primary PCI on infarct size
evaluated by MRI (2). Patients randomized to intra-
venous metoprolol received up to 3 boluses of 5 mg
metoprolol tartrate before reperfusion, of whom 55%
already received metoprolol during ambulance
transfer to the hospital. They showed that early
administration of intravenous metoprolol before
reperfusion was safe to use and reduced infarct size
assessed by MRI by 20% and creatine kinase release
by 21%. In addition, it resulted in a higher left ven-
tricular ejection fraction, a reduced incidence of
severe left ventricular systolic dysfunction and
implantable cardioverter-deﬁbrillator indications,
and fewer heart failure admissions both during the
ﬁrst 24 h after STEMI as well as at 6-month follow-up
(2,4). A subgroup analysis of this trial revealed that
out-of-hospital administration of intravenous meto-
prolol by emergency medical services did not result in
an excess of adverse events during the ﬁrst 24 h (5).
Despite the differences in the timing of beta-blocker
administration, both the METOCARD-CNIC trial and
the present study show that early administration of
beta-blockers is effective, with remarkable similar-
ities regarding cardiac enzyme release.The mechanisms by which early administration
of beta-blockers modulates sympathetic activity and
improves outcome in patients with acute myocardial
infarction is a matter of experimental research. One
of the mechanisms proposed is that beta-blockers play
a role in preventing the cardiotoxic effects of cate-
cholamines released by the adrenergic response to
myocardial infarction. The anti-ischemic action
of beta-blockers can be attributed to a decreased
myocardial oxygen demand by reducing heart rate,
cardiac contractility, and systolic blood pressure (6).
In addition, the elongation of the diastolic phase
caused by the chronotropic effects of beta-blockers
may increase myocardial perfusion (1). Another pro-
posed mechanism is that beta-blockers diminish the
proinﬂammatory monocyte response after STEMI,
probably secondary to the interaction between bone
marrow and the spleen (7,8). The acute systemic
inﬂammation aimed at repair of the injured heart
could also impair cardiac regeneration and accelerate
pre-existing chronic atherosclerosis (7). Monocytes
play an important role in infarct healing; however, it
has been reported that a proinﬂammatory monocyte
response characterized by high levels of classic
monocytes may impair cardiac regeneration and
directly affect prognosis (9–12).
Rapid reperfusion remains the cornerstone of
contemporary STEMI care. Considering the adjunctive
therapies, evidence is accumulating that early
administration of beta-blockers is a safe, promising,
low-cost therapeutic strategy to further improve
clinical outcome in patients with acute coronary syn-
dromes. However, more research is needed to conﬁrm
these promising ﬁndings in larger randomized clinical
trials designed to elucidate the mechanisms of action.
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